stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Free cash flow
Teva Pharmaceutical Industries Ltd.'s free cash flow for fiscal 2025 was $1.2B, up 49.2% from $792.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.3B. Over the past ten years it has ranged from $547.0M (fiscal 2021) to $6.3B (fiscal 2016); the current reading is higher than 64% of that period. Teva Pharmaceutical Industries Ltd. ranks 5th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.2B | 49.24% |
| FY2024 | $792.0M | (12.97%) |
| FY2023 | $910.0M | (18.02%) |
| FY2022 | $1.1B | 102.93% |
| FY2021 | $547.0M | (22.41%) |
| FY2020 | $705.0M | 24.56% |
| FY2019 | $566.0M | (78.92%) |
| FY2018 | $2.7B | (44.39%) |
| FY2017 | $4.8B | (23.68%) |
| FY2016 | $6.3B | 19.49% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $168.0M | (45.81%) |
| Jun 2026 | $310.0M | — |
| Mar 2026 | −$166.0M | — |
| Dec 2025 | $1.0B | 321.58% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.0B |
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| VTRS Viatris Inc. compare | $2.4B |
| ZTS Zoetis Inc. compare | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. | $1.3B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement